Syner-KINASE® (urokinase) is a medicinal product containing the protein urokinase derived from human urine
Syner-KINASE® (urokinase)
It is presented as a lyophilised powder in vials each containing 10,000, 25,000, 100,000, 250,000 or 500,000 International Units (IU) for the treatment of thrombosed catheters and systemic thromboembolic occlusive disease (diseases caused by blood clots).
Therapeutic Indications
Syner-KINASE® is indicated for the lysis of blood clots in the following conditions:
- thrombosed intravascular catheters and cannulae
- extensive acute proximal deep vein thrombosis
- acute massive pulmonary embolism
- acute occlusive peripheral arterial disease with limb threatening ischemia
License statement
Syner-KINASE® (urokinase) is licensed in Great Britain and in France, Germany, Spain and the Netherlands under other associated names.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine. Adverse events should also be reported to Syner-Med (Pharmaceutical Products) Limited. Tel. +44 020 8655 6380 (Option 1).
Policy
Privacy Policy
Cookie Policy
Data Protection Policy
Slavery & Human Trafficking Statement
Cookie Policy
Data Protection Policy
Slavery & Human Trafficking Statement
Syner-Med publicly discloses information about its clinical trials in external public registries, such as EU Clinical Trials Register via https://www.clinicaltrialsregister.eu
